World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
143
Citations
104889
World Ranking
1474
National Ranking
859

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

George D. Demetri is affiliated with the Dana-Farber Cancer Institute in the United States. Their research focuses primarily on the fields of Medicine, with a particular emphasis on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Gastroenterology, and Pathology and Forensic Medicine.

Their scholarly work covers significant topics including Sarcoma Diagnosis and Treatment, Gastrointestinal Tumor Research and Treatment, COVID-19 and healthcare impacts, Vascular Tumors and Angiosarcomas, COVID-19 Clinical Research Studies, CAR-T cell therapy research, and Lymphoma Diagnosis and Treatment.

Frequent coauthors working alongside them include:

  • Suzanne George
  • Gregory M. Coté
  • Jason L. Hornick
  • Priscilla Merriam
  • Chandrajit P. Raut

George D. Demetri has published regularly in notable scientific venues such as:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • The Lancet Oncology
  • Nature Medicine

Among recent papers authored or coauthored by George D. Demetri are:

  • Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study, 2020, The Lancet Oncology
  • The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research, 2020, Nature Medicine
  • Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19, 2021, JAMA Oncology
  • Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer, 2022, JAMA Network Open
  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin, 2020, UNC Libraries

George D. Demetri received the distinction of being a Member of the Association of American Physicians. This recognition reflects their professional standing within the medical research community.

Best Publications

  • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

    George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

    Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey

  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

    Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke

  • Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor

    Heikki Joensuu;Peter J. Roberts;Maarit Sarlomo-Rikala;Leif C. Andersson

  • Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

    Ronald P. DeMatteo;Karla V. Ballman;Cristina R. Antonescu;Robert G. Maki

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

    Thomas J. Smith;James Khatcheressian;Gary H. Lyman;Howard Ozer

  • 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*

    Thomas J. Smith;Howard Ozer;Langdon L. Miller;Charles A. Schiffer

  • Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

    Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • Granulocyte colony-stimulating factor and its receptor.

    GD Demetri;JD Griffin

  • Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

    Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich

  • NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors

    George D. Demetri;Margaret Von Mehren;Cristina R. Antonescu;Ronald P. DeMatteo

  • KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

    Brian P. Rubin;Samuel Singer;Connie Tsao;Anette Duensing

  • Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

    Tammy F Chu;Tammy F Chu;Maria A Rupnick;Maria A Rupnick;Risto Kerkela;Susan M Dallabrida

Frequent Co-Authors

Jonathan A. Fletcher
Jonathan A. Fletcher Brigham and Women's Hospital
Suzanne George
Suzanne George Harvard University
Robert G. Maki
Robert G. Maki University of Pennsylvania
Christopher D.M. Fletcher
Christopher D.M. Fletcher Brigham and Women's Hospital
Michael Heinrich
Michael Heinrich Oregon Health & Science University
Chandrajit P. Raut
Chandrajit P. Raut Brigham and Women's Hospital
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Heikki Joensuu
Heikki Joensuu University of Helsinki
Paolo G. Casali
Paolo G. Casali University of Milan
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean attending traditional, on-campus programs. Today, aspiring healthcare professionals can choose online degrees tailored to their career goals and schedules. For those interested in healthcare administration, top online mha programs that are cahme accredited offer flexibility and respected accreditation, ensuring quality education for future leaders.

Nursing professionals seeking advancement can benefit from rn bsn online programs no clinicals, which allow registered nurses to earn their bachelor's degree without additional clinical requirements. This is ideal for working nurses balancing their studies with professional responsibilities.

If you are considering a terminal nursing degree, there are options for accelerated paths such as the shortest online dnp program for those who want to progress quickly. For greater flexibility and accessibility, online dnp programs can accommodate diverse backgrounds and schedules.

Exploring these online medical and healthcare degrees can provide new opportunities for career advancement while fitting your lifestyle and ambitions.

Best Scientists Citing George D. Demetri

Trending Scientists

Recently Published Articles